Eucommia, Cuscuta, and Drynaria Extracts Ameliorate Glucocorticoid-Induced Osteoporosis by Inhibiting Osteoclastogenesis Through PI3K/Akt Pathway
出版年份 2022 全文链接
标题
Eucommia, Cuscuta, and Drynaria Extracts Ameliorate Glucocorticoid-Induced Osteoporosis by Inhibiting Osteoclastogenesis Through PI3K/Akt Pathway
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-02-04
DOI
10.3389/fphar.2021.772944
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of anti-osteoporotic medications in patients with rebound-associated fractures after denosumab discontinuation
- (2021) Athanasios D. Anastasilakis et al. JOURNAL OF CLINICAL DENSITOMETRY
- Interleukin‑1 induces receptor activator of nuclear factor‑κB ligand‑independent osteoclast differentiation in RAW264.7 cells
- (2021) Rongdong Liao et al. Experimental and Therapeutic Medicine
- RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling
- (2020) Mohammad Tobeiha et al. Biomed Research International
- Triptolide prevents bone loss via suppressing osteoclastogenesis through inhibiting PI3K‐AKT‐NFATc1 pathway
- (2020) Jin Cui et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment
- (2020) Pojchong Chotiyarnwong et al. Nature Reviews Endocrinology
- Ganoderma lucidum Immune Modulator Protein rLZ-8 Could Prevent and Reverse Bone Loss in Glucocorticoids-Induced Osteoporosis Rat Model
- (2020) Yong Yang et al. Frontiers in Pharmacology
- 3,5-dicaffeoyl‑epi-quinic acid from Atriplex gmelinii enhances the osteoblast differentiation of bone marrow-derived human mesenchymal stromal cells via WnT/BMP signaling and suppresses adipocyte differentiation via AMPK activation
- (2020) Fatih Karadeniz et al. PHYTOMEDICINE
- Osteoblast-Osteoclast Communication and Bone Homeostasis
- (2020) Jung-Min Kim et al. Cells
- Daphnetin ameliorates glucocorticoid-induced osteoporosis via activation of Wnt/GSK-3β/β-catenin signaling
- (2020) Yongkui Wang et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Osteoporosis
- (2019) Juliet E Compston et al. LANCET
- Regulation of Proliferation, Differentiation and Functions of Osteoblasts by Runx2
- (2019) Toshihisa Komori INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Concise Review: Mesenchymal Stem Cells: From Roots to Boost
- (2019) Anna Andrzejewska et al. STEM CELLS
- Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade
- (2019) Jeong-Tae Yeon et al. ARCHIVES OF PHARMACAL RESEARCH
- Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis
- (2019) Yanan An et al. FASEB JOURNAL
- Therapeutic Anabolic and Anticatabolic Benefits of Natural Chinese Medicines for the Treatment of Osteoporosis
- (2019) Jianbo He et al. Frontiers in Pharmacology
- Runx2, an inducer of osteoblast and chondrocyte differentiation
- (2018) Toshihisa Komori HISTOCHEMISTRY AND CELL BIOLOGY
- Tumor Necrosis Factor Alpha Promotes Osteoclast Formation Via PI3K/Akt Pathway-Mediated Blimp1 Expression Upregulation
- (2017) LeCheng Wu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Osteoporosis treatment: recent developments and ongoing challenges
- (2017) Sundeep Khosla et al. Lancet Diabetes & Endocrinology
- Chlorogenic Acid Prevents Osteoporosis by Shp2/PI3K/Akt Pathway in Ovariectomized Rats
- (2017) Rong Ping Zhou et al. PLoS One
- Fate decision of mesenchymal stem cells: adipocytes or osteoblasts?
- (2016) Q Chen et al. CELL DEATH AND DIFFERENTIATION
- Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
- (2016) Robert A Adler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation
- (2016) Jing An et al. LIFE SCIENCES
- Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression
- (2015) Xiang-zhou Zeng et al. ACTA PHARMACOLOGICA SINICA
- Bromo-honaucin A inhibits osteoclastogenic differentiation in RAW 264.7 cells via Akt and ERK signaling pathways
- (2015) Mahesh Sapkota et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The PI3K/AKT/mTOR interactive pathway
- (2015) Tulin Ersahin et al. Molecular BioSystems
- miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway
- (2015) Chenyang Zhao et al. RNA Biology
- Potential Antiosteoporotic Agents from Plants: A Comprehensive Review
- (2013) Min Jia et al. Evidence-based Complementary and Alternative Medicine
- Ethanol Extracts of FreshDavallia formosana(WL1101) Inhibit Osteoclast Differentiation by Suppressing RANKL-Induced Nuclear Factor-κB Activation
- (2013) Tzu-Hung Lin et al. Evidence-based Complementary and Alternative Medicine
- Osteoprotegerin influences the bone resorption activity of osteoclasts
- (2013) YING-XIAO FU et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Glucocorticoid-induced osteoporosis: An update on effects and management
- (2013) Bjoern Buehring et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Pathophysiology of Osteoporosis
- (2012) Laura A.G. Armas et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Akt Induces Osteoclast Differentiation through Regulating the GSK3 /NFATc1 Signaling Cascade
- (2011) J. B. Moon et al. JOURNAL OF IMMUNOLOGY
- Denosumab: Anti-RANKL antibody
- (2009) Paul D. Miller Current Osteoporosis Reports
- Functions of RANKL/RANK/OPG in bone modeling and remodeling
- (2008) Brendan F. Boyce et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment
- (2008) Kousuke Iba et al. JOURNAL OF ORTHOPAEDIC SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More